Private equity firm Carlyle Group is in exclusive discussions to purchase Baxter International’s kidney care spinoff, Vantive, in a deal valued at around $4bn including debt, according to reports by Reuters and the Wall Street Journal.
The report cites an unnamed source in revealing that the parties entered exclusive negotiations in late June, and an announcement over a deal could be made in the coming weeks.
Shares of Baxter International, based in Deerfield, Illinois, have risen by more than 4% since news of the potential deal broke.
In March, Baxter announced it was exploring the sale of its kidney care unit with select private equity investors. The decision came more than a year after Baxter revealed plans to separate the unit due to supply chain challenges and weak demand for dialysis operations. The company aims to complete the separation in the second half of the year.
Can’t stop reading? Read more
US Pipeline Operator ONEOK Inks Two Deals for $5.9 Billion
US pipeline operator ONEOK Inc. agreed to buy a Permian Basin rival and a controlling stake in...
Blackstone Is Said to Seek A$5.5 Billion Loan for AirTrunk Bid
Private equity firm Blackstone Inc. is in discussions with banks for a five-year loan of about...
Thrive Capital to lead multi-billion dollar OpenAI investment round at $100bn valuation
OpenAI, the company behind the popular AI tool ChatGPT, is in advanced talks to secure several...